TABLE 3

Currently available ocular drug-delivery systems in clinical trials for the treatment of posterior segment disorders (Kang-Mieler et al., 2014)

DrugBrand NameMode of AdministrationExcipient Controlling Release Characteristic of DrugTarget IndicationDevelopmental StageClinical Trial #
DexamethasoneOzurdex (Allergan)Intravitreal implantPLGA (Novadur)Macular edema Posterior uveitisLaunchedNCT01427751
GanciclovirVitrasert (Auritec Pharmaceuticals Inc.)Intravitreal implantPVA/EVACMV retinitisLaunchedNCT00000135
Fluocinolone acetonideRetisert (Bausch & Lomb)Intravitreal implantPVAPosterior uveitisLaunchedNCT00570830
VerteporfinVisudyne (Bausch & Lomb)i.v. injectionLiposomeWet AMDLaunchedNCT00242580
DexamethasoneDexycu (EyePoint Pharmaceuticals, Inc.)Intravitreal implantAcetyl triethyl citratePostoperative inflammationLaunchedNCT02547623
DifluprednateDurezol (Novartis Pharmaceuticals)Eye dropsEmulsionDMEOff-labelNCT00429923
BetamethasoneIntravitreal implantChronijectDMEPhase II/IIINCT01546402
CNTF (NT-501)Renexus (Neurotech Pharmaceuticals)Intravitreal implantSemipermeable hollow fiber membrane/NTC-200Atrophic AMDPhase II/IIINCT03316300
Phase II
DexamethasoneEye dropsCyclodextrin microparticlesDMEPhase II/IIINCT01523314
Fluocinolone acetonideIluvien (Alimera Sciences)Intravitreal implantPolyamide/PVAPosterior uveitisPhase IVNCT01304706
Macular edemaPhase II/III
Wet AMDPhase II
Triamcinolone acetonide with ranibizumabIntravitreal injectionVerisomeWet AMDPhase II/IIINCT02806752
BrimonidineIntravitreal implantPLGADry AMDPhase IINCT02087085
RPPhase I/II
Triamcinolone acetonide (IBI-20089)Intravitreal implantBenzyl benzoateWet AMDPhase IINCT01175395
Triamcinolone acetonide (RETAAC)Intravitreal implantPLGADMEPhase I/IINCT00407849
Dexamethasone prodrug (NOVA-63035)Cortiject (Novagali Pharma S.A)Intravitreal implantEmulsionDMEPhase INCT00665106
RanibizumabDrug portRefillable portWet AMDPhase INCT03677934
VEGFR-Fc (NT-503)Intravitreal implantSemipermeable hollow fiber membrane/NTC-200Wet AMDPhase INCT02228304
Human embryonic stem cell–derived retinal pigment epithelium (MA09-hRPE) cellsCells transplantation via subretinal injectionCell suspensionAdvanced dry AMDPhaseI/IINCT01344993
AR-1105 (dexamethasone implant)Intravitreal implantBiodegradable implantMacular edema due to RVOPhase IINCT03739593
  • CMV retinitis, cytomegalovirus retinitis; CNTF, ciliary neurotrophic factor; EVA, Ethylene-vinyl acetate copolymer; PVA, Poly(vinyl alcohol); RP, Retinitis pigmentosa.